BEAM
Beam Therapeutics Inc
$24.90
0.29 (1.20%) Today
0.38 (1.55%) After-hours
— up— down
Market Cap
$2.50B+2.6%
Revenue (TTM)
$153.87M+158.9%
Net Income (TTM)
$-83,816,336
$-83,816,336EPS (TTM)
-0.81
-0.81Shares Out
102.88M
102.88MOpen
$24.14
$24.14Previous Close
$24.23
$24.23Day Range
$23.89 – $24.76
$23.89 – $24.7652-Week Range
$20.23 – $38.26
$20.23 – $38.26Beta
2.26
2.26Volume
1.63M
1.63MAvg Volume
2.08M
2.08MAnalyst Rating
Buy
BuyExchange
NASDAQ NMS - GLOBAL MARKET
NASDAQ NMS - GLOBAL MARKETAbout BEAM
Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR base editing and prime editing, whereby single nucleotides in a DNA sequence can be enzymatically modified without producing double-strand breaks.
Related
News
Beam Therapeutics: Ignore The Anthropic Noise And Focus On Clinical Progress
SeekingAlpha · 16h ago
As Claude Enters the Gene-Editing Arena, There’s Still a Long-Term Case for BEAM Stock
Yahoo · 1d ago
Crispr Therapeutics: Why AI Giant Anthropic's Discovery Has Rocked Gene Editing
SeekingAlpha · 5d ago
Beam Therapeutics (BEAM) Stock Could Trade At A Premium As Gene Editing Interest Grows
Yahoo · 5d ago
CRISPR Therapeutics Traded Sideways and Down for 12 Months: One Wall Street Pro Expects 85% Gains Soon
Yahoo · 6d ago